NewAmsterdam Pharma Co N.V. (NAMSW) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
GOOIMEER 2-35 NARRDEN, 1411 DC |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 340,450 | |||
| Cash and cash equivalents | 340,450 | |||
| Receivables | 1,881 | |||
| Prepaid expense | 2,123 | |||
| Other undisclosed current assets | 2,337 | |||
| Total current assets: | 346,791 | |||
| Noncurrent Assets | ||||
| Operating lease, right-of-use asset | 55 | |||
| Property, plant and equipment | 46 | |||
| Intangible assets, net (including goodwill), including: | 170 | |||
| Other undisclosed intangible assets, net (including goodwill) | 170 | |||
| Prepaid expense | 35 | |||
| Total noncurrent assets: | 306 | |||
| TOTAL ASSETS: | 347,097 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 22,376 | |||
| Accounts payable | 16,923 | |||
| Accrued liabilities | 5,453 | |||
| Deferred revenue | 8,942 | |||
| Derivative instruments and hedges, liabilities | 12,574 | |||
| Other undisclosed current liabilities | 6,005 | |||
| Total current liabilities: | 49,897 | |||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 8,807 | |||
| Deferred revenue | 1,019 | |||
| Operating lease, liability | ||||
| Derivative instruments and hedges, liabilities | 7,788 | |||
| Total noncurrent liabilities: | 8,807 | |||
| Total liabilities: | 58,704 | |||
| Equity | ||||
| Equity, attributable to parent | 288,393 | |||
| Common stock | 10,173 | |||
| Additional paid in capital | 590,771 | |||
| Accumulated other comprehensive income | 4,422 | |||
| Accumulated deficit | (316,973) | |||
| Total equity: | 288,393 | |||
| TOTAL LIABILITIES AND EQUITY: | 347,097 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | ||
|---|---|---|---|
| Revenues | 14,090 | ||
| Gross profit: | 14,090 | ||
| Operating expenses | (197,057) | ||
| Operating loss: | (182,967) | ||
| Nonoperating income | 16,341 | ||
| Investment income, nonoperating | 11,283 | ||
| Gain, foreign currency transaction, before tax | 5,058 | ||
| Loss from continuing operations before equity method investments, income taxes: | (166,626) | ||
| Other undisclosed loss from continuing operations before income taxes | (10,284) | ||
| Loss from continuing operations before income taxes: | (176,910) | ||
| Income tax expense (benefit) | (27) | ||
| Net loss available to common stockholders, diluted: | (176,937) | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | ||
|---|---|---|---|
| Net loss: | (176,937) | ||
| Comprehensive loss, net of tax, attributable to parent: | (176,937) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.